Elite Clinical Network (ECN) is pleased to announce the appointment of C.G. “Chip” Gillooly as an Operating Partner and member of the Board of Directors. With his extensive experience and proven track record working with sponsors, partners, and investors to advance critical new therapies, Chip will play a pivotal role in helping ECN continue to grow and meet the increasingly demanding and complex requirements of today’s research studies.
Chip’s sector experience includes more than a decade at Quintiles (now IQVIA) where as a member of NovaQuest, the strategic investing and partnering arm of Quintiles, he led a global team that worked with emerging and mid-size biotechs to advance new therapies. Following Quintiles, Chip served as CEO of Cognitive Research Corporation, a rapidly growing, therapeutically focused CRO targeting the CNS markets.
As Operating Partner to ECN and Surge, Chip will work with the board and leadership team to manage the rapid growth the company is experiencing and secure increased enterprise value for the firm.
Sanjay Gulati, Principal at Surge, said, “We are confident that Chip’s comprehensive knowledge of the clinical services landscape will help us maximize the potential of ECN as the industry increasingly relies on site networks to advance new therapies.”
“I am super excited and grateful to be joining this company and this leadership team at this critical moment in time. There are seismic shifts taking place in the clinical services industry that are elevating the importance of site organizations and their impact on drug development. This fluid environment will demand thoughtful, strategic actions by key players to succeed. I look forward to helping our teams succeed in this highly competitive and dynamic market,” said Gillooly.